Cargando…
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials
BACKGROUND: Data from two trials of panitumumab in metastatic colorectal cancer (mCRC) were retrospectively analysed to investigate the effects of primary tumour location on early-tumour shrinkage (ETS) and depth of response (DpR), and identify factors predicting long-term survival. METHODS: Patient...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068172/ https://www.ncbi.nlm.nih.gov/pubmed/30013091 http://dx.doi.org/10.1038/s41416-018-0165-z |
_version_ | 1783343221665955840 |
---|---|
author | Peeters, Marc Price, Timothy Taieb, Julien Geissler, Michael Rivera, Fernando Canon, Jean-Luc Pentheroudakis, George Koukakis, Reija Burdon, Peter Siena, Salvatore |
author_facet | Peeters, Marc Price, Timothy Taieb, Julien Geissler, Michael Rivera, Fernando Canon, Jean-Luc Pentheroudakis, George Koukakis, Reija Burdon, Peter Siena, Salvatore |
author_sort | Peeters, Marc |
collection | PubMed |
description | BACKGROUND: Data from two trials of panitumumab in metastatic colorectal cancer (mCRC) were retrospectively analysed to investigate the effects of primary tumour location on early-tumour shrinkage (ETS) and depth of response (DpR), and identify factors predicting long-term survival. METHODS: Patients with RAS wild-type mCRC from PRIME (NCT00364013) and PEAK (NCT00819780) were included. ETS was defined as a ≥30% reduction in the sum-of-the-longest-diameters of measurable target lesions at eight weeks. DpR was the maximum percentage change from baseline to nadir in patients with shrinkage. Univariate and multivariate logistic analyses of short- versus long-term survivor data were performed. RESULTS: A total of 435/559 (78%) patients had left-sided disease. Of these, a higher proportion of patients treated with panitumumab versus comparator achieved ETS (PRIME: 62% vs. 36%; PEAK: 58% vs. 41%); median DpR was also higher with panitumumab (PRIME: 59% vs. 49%; PEAK: 70% vs. 48%). In pooled analyses of the studies, more patients with right-sided disease achieved ETS if treated with panitumumab than comparator (39% vs. 29%). Panitumumab treatment consistently predicted long-term survival. CONCLUSIONS: First-line panitumumab was associated with improved ETS and DpR vs. comparator in patients with left-sided mCRC. ETS may identify a subgroup of patients with right-sided disease who might respond to panitumumab. |
format | Online Article Text |
id | pubmed-6068172 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-60681722019-06-25 Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials Peeters, Marc Price, Timothy Taieb, Julien Geissler, Michael Rivera, Fernando Canon, Jean-Luc Pentheroudakis, George Koukakis, Reija Burdon, Peter Siena, Salvatore Br J Cancer Article BACKGROUND: Data from two trials of panitumumab in metastatic colorectal cancer (mCRC) were retrospectively analysed to investigate the effects of primary tumour location on early-tumour shrinkage (ETS) and depth of response (DpR), and identify factors predicting long-term survival. METHODS: Patients with RAS wild-type mCRC from PRIME (NCT00364013) and PEAK (NCT00819780) were included. ETS was defined as a ≥30% reduction in the sum-of-the-longest-diameters of measurable target lesions at eight weeks. DpR was the maximum percentage change from baseline to nadir in patients with shrinkage. Univariate and multivariate logistic analyses of short- versus long-term survivor data were performed. RESULTS: A total of 435/559 (78%) patients had left-sided disease. Of these, a higher proportion of patients treated with panitumumab versus comparator achieved ETS (PRIME: 62% vs. 36%; PEAK: 58% vs. 41%); median DpR was also higher with panitumumab (PRIME: 59% vs. 49%; PEAK: 70% vs. 48%). In pooled analyses of the studies, more patients with right-sided disease achieved ETS if treated with panitumumab than comparator (39% vs. 29%). Panitumumab treatment consistently predicted long-term survival. CONCLUSIONS: First-line panitumumab was associated with improved ETS and DpR vs. comparator in patients with left-sided mCRC. ETS may identify a subgroup of patients with right-sided disease who might respond to panitumumab. Nature Publishing Group UK 2018-07-17 2018-08-01 /pmc/articles/PMC6068172/ /pubmed/30013091 http://dx.doi.org/10.1038/s41416-018-0165-z Text en © The Author(s) 2018 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Peeters, Marc Price, Timothy Taieb, Julien Geissler, Michael Rivera, Fernando Canon, Jean-Luc Pentheroudakis, George Koukakis, Reija Burdon, Peter Siena, Salvatore Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials |
title | Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials |
title_full | Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials |
title_fullStr | Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials |
title_full_unstemmed | Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials |
title_short | Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials |
title_sort | relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with ras wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the prime and peak clinical trials |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068172/ https://www.ncbi.nlm.nih.gov/pubmed/30013091 http://dx.doi.org/10.1038/s41416-018-0165-z |
work_keys_str_mv | AT peetersmarc relationshipsbetweentumourresponseandprimarytumourlocationandpredictorsoflongtermsurvivalinpatientswithraswildtypemetastaticcolorectalcancerreceivingfirstlinepanitumumabtherapyretrospectiveanalysesoftheprimeandpeakclinicaltrials AT pricetimothy relationshipsbetweentumourresponseandprimarytumourlocationandpredictorsoflongtermsurvivalinpatientswithraswildtypemetastaticcolorectalcancerreceivingfirstlinepanitumumabtherapyretrospectiveanalysesoftheprimeandpeakclinicaltrials AT taiebjulien relationshipsbetweentumourresponseandprimarytumourlocationandpredictorsoflongtermsurvivalinpatientswithraswildtypemetastaticcolorectalcancerreceivingfirstlinepanitumumabtherapyretrospectiveanalysesoftheprimeandpeakclinicaltrials AT geisslermichael relationshipsbetweentumourresponseandprimarytumourlocationandpredictorsoflongtermsurvivalinpatientswithraswildtypemetastaticcolorectalcancerreceivingfirstlinepanitumumabtherapyretrospectiveanalysesoftheprimeandpeakclinicaltrials AT riverafernando relationshipsbetweentumourresponseandprimarytumourlocationandpredictorsoflongtermsurvivalinpatientswithraswildtypemetastaticcolorectalcancerreceivingfirstlinepanitumumabtherapyretrospectiveanalysesoftheprimeandpeakclinicaltrials AT canonjeanluc relationshipsbetweentumourresponseandprimarytumourlocationandpredictorsoflongtermsurvivalinpatientswithraswildtypemetastaticcolorectalcancerreceivingfirstlinepanitumumabtherapyretrospectiveanalysesoftheprimeandpeakclinicaltrials AT pentheroudakisgeorge relationshipsbetweentumourresponseandprimarytumourlocationandpredictorsoflongtermsurvivalinpatientswithraswildtypemetastaticcolorectalcancerreceivingfirstlinepanitumumabtherapyretrospectiveanalysesoftheprimeandpeakclinicaltrials AT koukakisreija relationshipsbetweentumourresponseandprimarytumourlocationandpredictorsoflongtermsurvivalinpatientswithraswildtypemetastaticcolorectalcancerreceivingfirstlinepanitumumabtherapyretrospectiveanalysesoftheprimeandpeakclinicaltrials AT burdonpeter relationshipsbetweentumourresponseandprimarytumourlocationandpredictorsoflongtermsurvivalinpatientswithraswildtypemetastaticcolorectalcancerreceivingfirstlinepanitumumabtherapyretrospectiveanalysesoftheprimeandpeakclinicaltrials AT sienasalvatore relationshipsbetweentumourresponseandprimarytumourlocationandpredictorsoflongtermsurvivalinpatientswithraswildtypemetastaticcolorectalcancerreceivingfirstlinepanitumumabtherapyretrospectiveanalysesoftheprimeandpeakclinicaltrials |